Clinical pharmacogenetics implementation consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype

K. R. Crews, A. Gaedigk, H. M. Dunnenberger, T. E. Klein, D. D. Shen, John Callaghan, E. D. Kharasch, Todd Skaar

Research output: Contribution to journalArticle

243 Citations (Scopus)

Abstract

Codeine is bioactivated to morphine, a strong opioid agonist, by the hepatic cytochrome P450 2D6 (CYP2D6); hence, the efficacy and safety of codeine as an analgesic are governed by CYP2D6 polymorphisms. Codeine has little therapeutic effect in patients who are CYP2D6 poor metabolizers, whereas the risk of morphine toxicity is higher in ultrarapid metabolizers. The purpose of this guideline (periodically updated at http://www.pharmgkb.org) is to provide information relating to the interpretation of CYP2D6 genotype test results to guide the dosing of codeine.

Original languageEnglish
Pages (from-to)321-326
Number of pages6
JournalClinical Pharmacology and Therapeutics
Volume91
Issue number2
DOIs
StatePublished - Feb 2012

Fingerprint

Codeine
Cytochrome P-450 CYP2D6
Pharmacogenetics
Genotype
Guidelines
Morphine
Therapeutic Uses
Therapeutics
Opioid Analgesics
Analgesics
Safety
Liver

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Clinical pharmacogenetics implementation consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. / Crews, K. R.; Gaedigk, A.; Dunnenberger, H. M.; Klein, T. E.; Shen, D. D.; Callaghan, John; Kharasch, E. D.; Skaar, Todd.

In: Clinical Pharmacology and Therapeutics, Vol. 91, No. 2, 02.2012, p. 321-326.

Research output: Contribution to journalArticle

@article{26ea8ead34d340a59376e15fd10822a9,
title = "Clinical pharmacogenetics implementation consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype",
abstract = "Codeine is bioactivated to morphine, a strong opioid agonist, by the hepatic cytochrome P450 2D6 (CYP2D6); hence, the efficacy and safety of codeine as an analgesic are governed by CYP2D6 polymorphisms. Codeine has little therapeutic effect in patients who are CYP2D6 poor metabolizers, whereas the risk of morphine toxicity is higher in ultrarapid metabolizers. The purpose of this guideline (periodically updated at http://www.pharmgkb.org) is to provide information relating to the interpretation of CYP2D6 genotype test results to guide the dosing of codeine.",
author = "Crews, {K. R.} and A. Gaedigk and Dunnenberger, {H. M.} and Klein, {T. E.} and Shen, {D. D.} and John Callaghan and Kharasch, {E. D.} and Todd Skaar",
year = "2012",
month = "2",
doi = "10.1038/clpt.2011.287",
language = "English",
volume = "91",
pages = "321--326",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Clinical pharmacogenetics implementation consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype

AU - Crews, K. R.

AU - Gaedigk, A.

AU - Dunnenberger, H. M.

AU - Klein, T. E.

AU - Shen, D. D.

AU - Callaghan, John

AU - Kharasch, E. D.

AU - Skaar, Todd

PY - 2012/2

Y1 - 2012/2

N2 - Codeine is bioactivated to morphine, a strong opioid agonist, by the hepatic cytochrome P450 2D6 (CYP2D6); hence, the efficacy and safety of codeine as an analgesic are governed by CYP2D6 polymorphisms. Codeine has little therapeutic effect in patients who are CYP2D6 poor metabolizers, whereas the risk of morphine toxicity is higher in ultrarapid metabolizers. The purpose of this guideline (periodically updated at http://www.pharmgkb.org) is to provide information relating to the interpretation of CYP2D6 genotype test results to guide the dosing of codeine.

AB - Codeine is bioactivated to morphine, a strong opioid agonist, by the hepatic cytochrome P450 2D6 (CYP2D6); hence, the efficacy and safety of codeine as an analgesic are governed by CYP2D6 polymorphisms. Codeine has little therapeutic effect in patients who are CYP2D6 poor metabolizers, whereas the risk of morphine toxicity is higher in ultrarapid metabolizers. The purpose of this guideline (periodically updated at http://www.pharmgkb.org) is to provide information relating to the interpretation of CYP2D6 genotype test results to guide the dosing of codeine.

UR - http://www.scopus.com/inward/record.url?scp=84855968708&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855968708&partnerID=8YFLogxK

U2 - 10.1038/clpt.2011.287

DO - 10.1038/clpt.2011.287

M3 - Article

C2 - 22205192

AN - SCOPUS:84855968708

VL - 91

SP - 321

EP - 326

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 2

ER -